These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19087271)

  • 1. LED-FISH: Fluorescence microscopy based on light emitting diodes for the molecular analysis of Her-2/neu oncogene amplification.
    Lang DS; Zeiser T; Schultz H; Stellmacher F; Vollmer E; Zabel P; Goldmann T
    Diagn Pathol; 2008 Dec; 3():49. PubMed ID: 19087271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
    Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
    Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous fluorescence immunophenotyping and Her-2/neu genotyping (FICTION) in breast carcinoma candidates to target therapy.
    Gatta LB; Incardona P; Cadei M; Grigolato P; Simoncelli S; Balzarini P
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):413-20. PubMed ID: 22417857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.
    Bozzetti C; Nizzoli R; Guazzi A; Flora M; Bassano C; Crafa P; Naldi N; Cascinu S
    Ann Oncol; 2002 Sep; 13(9):1398-403. PubMed ID: 12196365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
    Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
    Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples.
    Klijanienko J; Couturier J; Galut M; El-Naggar AK; Maciorowski Z; Padoy E; Mosseri V; Vielh P
    Cancer; 1999 Oct; 87(5):312-8. PubMed ID: 10536358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
    Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
    Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
    Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
    Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
    Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
    Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.
    Rosenthal SI; Depowski PL; Sheehan CE; Ross JS
    Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):40-6. PubMed ID: 11893034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
    Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
    J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy.
    Bose S; Mohammed M; Shintaku P; Rao PN
    Breast J; 2001; 7(5):337-44. PubMed ID: 11906444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.
    Moore JG; To V; Patel SJ; Sneige N
    Diagn Cytopathol; 2000 Nov; 23(5):299-302. PubMed ID: 11074621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.